• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2012 Product Image

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2012

  • Published: March 2012
  • 26 pages
  • Global Markets Direct

Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2012', provides an overview of the Uterine Leiomyoma (Uterine Fibroids) therapeutic pipeline. This report provides information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids). 'Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Uterine Leiomyoma READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Leiomyoma (Uterine Fibroids) Overview
Therapeutics Development
An Overview of Pipeline Products for Uterine Leiomyoma (Uterine Fibroids)
Uterine Leiomyoma (Uterine Fibroids) Therapeutics under Development by Companies
Uterine Leiomyoma (Uterine Fibroids) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Uterine Leiomyoma (Uterine Fibroids) Therapeutics – Products under Development by Companies
Uterine Leiomyoma (Uterine Fibroids) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Uterine Leiomyoma (Uterine Fibroids) Therapeutics Development
Abbott Laboratories
Uterine Leiomyoma (Uterine Fibroids) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Elagolix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mifepristone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uterine Leiomyoma (Uterine Fibroids) Therapeutics – Drug Profile Updates
Uterine Leiomyoma (Uterine Fibroids) – Product Development Milestones
Featured News & Press Releases
Aug 29, 2011: Takeda Initiates Phase II Clinical Trials Of TAK-385 In Japan
Jun 23, 2011: Repros Enrolls Fourth Cohort In Low Dose Proellex Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2012
Products under Development for Uterine Leiomyoma (Uterine Fibroids) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Abbott Laboratories, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Uterine Leiomyoma (Uterine Fibroids) Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2012
Products under Development for Uterine Leiomyoma (Uterine Fibroids) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos